Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 4/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6813615 | 0.98 | MAOB (0.95) | MAOBMAOATAAR1DPP4SLC6A3 | |
| SCHEMBL294582 | 0.91 | DPP4 (1.00) | MAOBMAOATAAR1DPP4SLC6A3 | |
| SCHEMBL294970 | 0.91 | DPP4 (0.91) | MAOBMAOATAAR1DPP4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809143 | 0.89 | DPP4 (0.96) | MAOBMAOATAAR1DPP4SLC6A3 | |
| Water SCHEMBL7260926 | 0.89 | DPP4 (0.88) | MAOBMAOATAAR1DPP4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809124 | 0.89 | DPP4 (0.88) | MAOBMAOATAAR1DPP4SLC6A3 | |
| SCHEMBL294761 | 0.89 | DPP4 (0.96) | MAOBMAOATAAR1DPP4SLC6A3 | |
| SCHEMBL17906515 | 0.87 | SLC6A3 (0.82) | MAOBMAOATAAR1DPP4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3520274 | 0.87 | DPP4 (0.92) | MAOBMAOATAAR1DPP4SLC6A3 | |
| SCHEMBL1492948 | 0.85 | MAOA (0.73) | MAOBMAOATAAR1DPP4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| EP-1601349-A1 | USE OF THE ENANTIOMER (1S, 2R) OF MILNACIPRAN FOR THE PREPARATION OF A MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2005-12-07 | — | — | EP | claimed |
| WO-2004075886-A1 | USE OF THE ENANTIOMER (1S, 2R) OF MILNACIPRAN FOR THE PREPARATION OF A MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2004-09-10 | — | — | WO | claimed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| EP-3990112-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI International (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3327027-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020264176-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-0232813-A2 | N6-substituted Adenosines | WARNER-LAMBERT COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0010401-B1 | NOVEL (1-SUBSTITUTED) CYCLOALKYLMETHYL-ISOTHIOCYANATES, A PROCESS FOR THEIR PREPARATION, COMPOSITIONS COMPRISING THEM, AND THEIR USE AS PESTICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-05-05 | — | — | EP | disclosed |
| US-4230878-A | AND 4-(UNSATURATED ALKYL)AMINOBENZOIC ACIDS AND DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4227014-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4216217-A | FUNGICIDES, INSECTICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-05 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4107326-A | ANTIHYPERTENSIVE AGENTS, DIURETICS | AMERICAN CYANAMID COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | MAOB 1853/4885MAOA 1717/4885TAAR1 1603/4885 |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR119 | MAOB 2025/4885MAOA 1690/4885TAAR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.